Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$1.16 USD
+0.04 (3.57%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.12 -0.04 (-3.45%) 7:28 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AXDX 1.16 +0.04(3.57%)
Will AXDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AXDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXDX
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
AXDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Other News for AXDX
Dead Cat Bounce: 3 Stocks to Sell Before They Plunge Again
Accelerate Diagnostics Unveils Executive Incentive Plan Linked to FDA Goals
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
Accelerate Diagnostics’ Shareholder Decisions at Annual Meeting